Correction: Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Bispecific Nanobodies Targeting Bet v 1 and ICAM-1 Reduce Penetration of Bet v 1 in Respiratory Epithelial Cells

  • By

  • Ines Zettl

  • Isabella Ellinger

  • Mohammed Zghaebi

  • Sarah Jance

  • Vanessa Izewski

  • Anja Drescher

  • Heimo Breiteneder

  • Manuel Röck

  • Martin Tollinger

  • Julia Eckl-Dorna

  • Sergei V. Tillib

  • Sabine Flicker

  • September 11, 2026

Share

  • 1

    The article corrects previous omissions by including a citation to a 2025 study on Bet v 1 and airway epithelial barrier penetration.

  • 2

    The correction revises the numbering sequence for references throughout the article to maintain accuracy.

  • 3

    Synthetic nanobody libraries maintain the nanobody scaffold while incorporating diverse complementarity-determining loops.

  • 4

    Transcytosis is recognized as a significant factor in Bet v 1 uptake, alongside paracellular penetration.

  • 5

    Recent findings show that Bet v 1 induces transcription of alarmins like IL-33 in airway epithelium, aiding transcellular penetration.

Original Source(s)

Correction: Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1

  • by Ines Zettl, Isabella Ellinger, Mohammed Zghaebi, Sarah Jance, Vanessa Izewski, Anja Drescher, Heimo Breiteneder, Manuel Röck, Martin Tollinger, Julia Eckl-Dorna, Sergei V. Tillib, Sabine Flicker

  • September 11, 2026

Related Content

Musings from The Power List: Ali Tavassoli

Ali Tavassoli explains how cyclic peptides and new discovery tools are opening up once-inaccessible biology

Favorable clinical and microbiological outcomes of a war-associated prosthetic joint infection caused by Klebsiella pneumoniae treated with combined phage-colistin therapy

Enterovirus diversity may limit treatment advances

Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.